Status:
NO_LONGER_AVAILABLE
Special Access for the Use of Voclosporin for Kidney Transplantation
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Immunosuppression
Transplantation, Kidney
Eligibility:
All Genders
18-65 years
Brief Summary
Voclosporin is an investigational medication previously studied to prevent acute rejection in patients who receive a kidney transplant. This study is a compassionate release program where subjects pre...
Detailed Description
Voclosporin is an investigational medication previously studied to prevent acute rejection in patients who receive a kidney transplant. This study is a compassionate release program where subjects pre...
Eligibility Criteria
Inclusion
- Subjects currently enrolled in "A Phase 2B, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) in denovo Renal Transplant Patients (ISA05-01)" and has a compelling reason to remain on voclosporin
- Subjects must provide Informed Consent to participate in this study
- Females of child-bearing potential must have a negative pregnancy test prior to enrollment
Exclusion
- Subjects who have already been switched off of voclosporin (ISA247) and on to another immunosuppressive agent
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01236287
Last Update
January 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College/NewYork-Presbyterian Hospital
New York, New York, United States, 10065